BPC-157: What Irish Researchers Need to Know in 2026

What Is BPC-157?

BPC-157, short for Body Protection Compound-157, is a synthetic pentadecapeptide — meaning it is composed of 15 amino acids. Its sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is derived from a naturally occurring protein found in human gastric juice. The parent protein was first isolated in the early 1990s by researchers in Croatia, and the isolated stable fragment — now known as BPC-157 — has since become one of the most frequently studied synthetic peptides in the preclinical literature.

Unlike many peptides that target a single receptor pathway, BPC-157 appears to exert effects across multiple biological systems simultaneously. This pleiotropic quality is what has driven sustained research interest over three decades, even in the absence of completed human clinical trials.

It is important to understand the distinction from the outset: virtually all published research on BPC-157 has been conducted in rodent models — primarily rats. The leap from rat physiology to human applicability involves significant scientific uncertainty, and no randomised controlled trial (RCT) in humans has been completed or published to date.

The Research Landscape in 2026

As of mid-2025, the majority of BPC-157 research consists of animal studies, primarily from the University of Zagreb group led by Predrag Sikiric and colleagues. Their body of work spans gastric ulcer healing, tendon repair, bone healing, central nervous system effects, cardiovascular protection, and wound healing across hundreds of published papers.

The breadth of findings in animal models is striking. BPC-157 has demonstrated effects on:

• Gastric mucosal protection and ulcer healing in rat models
• Tendon and ligament repair (Achilles tendon transection models)
• Bone fracture healing and remodelling
• Colitis and inflammatory bowel disease models
• Peripheral and central nervous system regeneration
• Modulation of dopaminergic and serotonergic pathways
• Reduction of NSAID-induced gastrointestinal damage

However, quantity of preclinical studies does not translate directly to clinical validity. The field of peptide research has seen numerous compounds that performed well in rodent models but failed in human trials or were never taken forward to human testing. BPC-157 remains in this preclinical category for now.

There is one notable exception: a related compound, PL 14736 (Pliva), reached Phase II clinical trials for inflammatory bowel disease in the mid-2000s. The results were inconclusive, and development was not continued. This lineage is relevant because it demonstrates that derivatives of the BPC research programme have reached human study, even if the specific BPC-157 sequence has not.

Proposed Mechanisms of Action

Understanding how BPC-157 is hypothesised to work requires looking at several parallel biological pathways. No single mechanism accounts for the breadth of observed preclinical effects; rather, the research points to convergent actions on tissue repair and homeostasis.

Angiogenesis and VEGF Pathways

One of the most consistently described mechanisms is the upregulation of vascular endothelial growth factor (VEGF) and the promotion of angiogenesis — the formation of new blood vessels. Adequate blood supply is fundamental to tissue repair; without oxygen and nutrient delivery, healing stalls. In tendon and wound-healing models, BPC-157 appears to accelerate the formation of new capillary networks, potentially explaining faster tissue repair timelines observed in animal studies.

Research published in Journal of Orthopaedic Research and other peer-reviewed journals has documented upregulated VEGF receptor expression following BPC-157 administration in rat tendon models. The compound appears to interact with the VEGFR2 pathway in particular, though the precise binding mechanism has not been fully characterised.

Tendon and Ligament Healing

Tendon injuries are notoriously slow to heal due to poor vascularity and low cell turnover. Multiple studies have examined BPC-157 in Achilles tendon transection models in rats, reporting accelerated tendon-to-bone healing, improved tensile strength in healing tendons, and earlier return to normal gait patterns compared to controls.

Proposed mechanisms include increased tenocyte proliferation, enhanced collagen organisation, and the VEGF-mediated angiogenesis described above. Some papers have also noted upregulation of growth hormone receptor expression in healing tendons following BPC-157 administration, which may facilitate downstream IGF-1 signalling at the injury site.

Gastrointestinal Mucosal Protection

The gastric protection effects are arguably the best-established in the literature, given that BPC-157 was originally isolated from gastric juice. In rat models, the compound has demonstrated protection against:

• Ethanol-induced gastric lesions
• NSAID (indomethacin, aspirin) induced ulceration
• Stress-induced gastric damage
• Cysteamine-induced duodenal ulcers

The proposed mechanisms here include upregulation of prostaglandin synthesis, modulation of nitric oxide (NO) systems, and direct cytoprotective effects on gastric epithelial cells. The NO system interaction is particularly interesting — BPC-157 appears to work through both NO-dependent and NO-independent pathways, suggesting it may complement rather than simply mimic prostaglandin-based gastroprotection.

Nitric Oxide System Interactions

A recurring theme across multiple research areas is BPC-157's interaction with the nitric oxide (NO) system. NO is a crucial signalling molecule in vascular regulation, immune function, and tissue repair. Studies have suggested BPC-157 can upregulate endothelial nitric oxide synthase (eNOS) expression, which may partially account for its observed vascular and cytoprotective effects. Importantly, the compound appears to retain activity even when NO pathways are pharmacologically blocked, suggesting additional mechanisms are at play.

Central Nervous System Effects

Animal models have examined BPC-157's effects on neurotransmitter systems, particularly dopaminergic and serotonergic pathways. Studies using various pharmacological perturbation models (overdose, withdrawal, lesion models) have reported modulatory effects. Some researchers have proposed that BPC-157 may act as a "GABAergic modulator" based on observed behavioural outcomes in rodent models of anxiety and depression, though this remains speculative and poorly characterised at the molecular level.

Research Protocols in the Published Literature

For those reading the primary literature, it is useful to understand the protocols typically employed in published studies. These are research protocols from peer-reviewed animal studies — they are not recommendations or protocols for human use.

The majority of studies have used one of two administration routes:

Intraperitoneal (IP) Injection in Rodents

The most common route in early BPC-157 literature. Doses in rat studies have typically ranged from 10 mcg/kg to 10 mg/kg body weight, with the 10 mcg/kg dose appearing most frequently in the Sikiric group's work. IP injection provides rapid systemic distribution but is not a practical route in most research settings outside of animal studies.

Subcutaneous (SC) Administration

More recent studies have used subcutaneous administration, often citing similar efficacy to IP dosing for many endpoints. Doses in the SC rat literature are broadly comparable to IP doses. Some studies have also explored oral administration routes, with several papers reporting activity for certain endpoints even via oral gavage — an unusual finding for peptides, which are typically degraded in the gastrointestinal tract.

Frequency and Duration

Most acute injury models use daily administration for 7–14 days following the injury event. Chronic model studies have used administration periods of 4–12 weeks. Studies examining CNS endpoints have often used shorter, more intensive protocols.

Reconstituting BPC-157 for Research

BPC-157 is typically supplied as a lyophilised (freeze-dried) powder in a sealed vial. Before it can be used in a research context, it must be reconstituted with an appropriate diluent. Bacteriostatic water is the standard choice for multi-use vials, as it contains 0.9% benzyl alcohol which inhibits microbial growth and extends the usable life of the reconstituted solution.

Calculating the correct volume of bacteriostatic water to achieve a desired concentration involves straightforward mathematics, but getting it right is critical for accurate dosing. Our free Peptide Reconstitution Calculator handles this calculation automatically — enter your vial size and desired concentration, and it will tell you exactly how much bacteriostatic water to add and what volume to draw for each dose.

Irish and EU Regulatory Context

This section is particularly important for anyone in Ireland or the European Union who encounters BPC-157 in the marketplace.

HPRA Position

The Health Products Regulatory Authority (HPRA) is the Irish competent authority for medicines regulation. BPC-157 does not hold a marketing authorisation from the HPRA for any therapeutic indication. It is not listed as an approved medicinal product in Ireland.

The HPRA classifies peptide compounds sold without proper authorisation as unlicensed medicinal products when they are presented as being for human therapeutic use. Supplying, distributing, or importing unlicensed medicinal products for human use without appropriate authorisation is a criminal offence under Irish medicines law, specifically the Medicinal Products (Prescription and Control of Supply) Regulations 2003 and associated legislation.

EMA Position

The European Medicines Agency (EMA) has not approved BPC-157 for any indication. The compound does not appear in the EMA's European Public Assessment Reports (EPARs), meaning no marketing authorisation application has been successfully completed at the EU level.

Research Exemptions

Academic and institutional research in the EU is subject to different regulatory frameworks than commercial supply. Researchers conducting work within licensed institutions, under appropriate ethics oversight, operate within a different legal context than individuals purchasing compounds for personal use. If you are conducting legitimate academic research involving peptide compounds, you should liaise directly with your institution's research governance office and, where appropriate, the HPRA, to ensure compliance.

Anti-Doping Status

BPC-157 is listed on the World Anti-Doping Agency (WADA) Prohibited List under the category of peptide hormones and related substances (S2). Any athlete subject to WADA code testing should be aware that the presence of BPC-157 would constitute a prohibited substance violation. This is relevant context for competitive athletes and coaches who encounter marketing for this compound.

What the Research Does — and Does Not — Tell Us

It is worth being clear-eyed about the state of the evidence. The preclinical literature on BPC-157 is genuinely interesting. The breadth and volume of positive findings in animal models is unusual, and the compound's apparent pleiotropic activity through multiple pathways gives it theoretical biological plausibility.

However, several important caveats apply:

• Animal-to-human translation is uncertain. Many compounds that perform well in rodent models fail in human trials, due to pharmacokinetic differences, dosing challenges, and biological complexity.
• The research base is concentrated. A significant proportion of the published BPC-157 literature originates from a single research group. Independent replication at scale is limited.
• No RCTs in humans exist. Without randomised controlled trials in human populations, efficacy and safety in humans cannot be established.
• Long-term safety data are absent. The preclinical literature does not comprehensively address long-term safety profiles, potential oncogenicity, or endocrine disruption.
• Oral bioavailability claims are contested. While some studies report activity via oral administration, the mechanisms by which a peptide would survive gastric degradation at meaningful concentrations remain poorly explained.

The absence of evidence for harm is also not evidence of safety, particularly for a compound that has not completed standard toxicological evaluation in preparation for human trials.